TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced four poster presentations at the 31st Annual Congress of the World Muscle Society (WMS).
This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.
Brief Summary
Satellos Bioscience Inc. is poised to make a significant impact at the 31st Annual Congress of the World Muscle Society. This prestigious event will showcase groundbreaking research in the field of muscle disease treatments.
- Four poster presentations highlighting innovative drug developments.
- Research targeted at degenerative muscle conditions.
- Expert insights from leading clinicians and researchers.
- Opportunities for collaboration and feedback.
Why it matters: This participation underlines Satellos’s commitment to advancing therapy options in muscle disease, potentially benefiting countless patients.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.